<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00129740</url>
  </required_header>
  <id_info>
    <org_study_id>2005-0048</org_study_id>
    <secondary_id>NCI-2012-01313</secondary_id>
    <nct_id>NCT00129740</nct_id>
  </id_info>
  <brief_title>Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)</brief_title>
  <official_title>Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Oral Nilotinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if an experimental agent, AMN107
      (nilotinib), can help to control CML in chronic phase. The safety of this experimental agent
      will also be studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nilotinib is a drug that is designed to block a protein that is responsible for the
      development of CML.

      If you are found to be eligible to take part in this study, you will take 2-4 nilotinib
      capsules or tablets by mouth 2 times a day (4-8 capsules or tablets a day total) every day,
      at least 8 hours apart. Nilotinib should be taken each morning and evening with a large glass
      of water. The study medication will be given to you every 3 - 12 months. You will also be
      given a &quot;pill diary&quot; to write down when (day and time) you take the drug. You will also write
      in the diary any side effects you may experience. You should bring the diary, any unused
      capsules or tablets, and empty containers of nilotinib with you to every visit to the study
      doctor. Any unused supplies must be returned at the end of the study.

      Every 1-4 weeks during the first 4 weeks of the study, you will have around 2 teaspoons of
      blood drawn for routine blood tests. The blood tests will then be repeated every 4-8 weeks
      (or more often if your doctor feels it is necessary) until you have been on study for 6
      months, then every 3 to 6 months for another 18 months. After that, you may have the blood
      tests repeated as often as the doctor thinks it is needed. A bone marrow sample will also be
      taken every 3-4 months for the first year and then every 6-12 months in the 2nd year, then
      every 2-3 years for as long as you are on the study to check on the status of the disease.
      Additionally, blood (about ½ tablespoon) will be drawn or a bone marrow sample will be
      collected every 3-4 months for the first year and then every 6-12 months until 2 years, and
      then about one time a year for as long as you are on the study to check on the status of the
      disease. However, if you are in complete remission after Year 2, your doctor will decide when
      you will have a bone marrow aspiration. But you will still have blood drawn (about ½
      tablespoon) every 1 - 3 years to check the status of your disease. An ECG will be repeated
      around Day 5, and then at about 6 weeks and about 3 months.

      You will be asked to visit the doctor for a physical exam and to have vital signs measured
      periodically. These visits will be scheduled at least every 3 to 4 months the first year.
      After the first year, the study staff will recommend that you have physical exams once every
      year. The visits may be scheduled more often depending on the status of the disease.

      Treatment may be continued for up to 8-10 years or as long as the doctor feels it is
      necessary to control the leukemia. If the disease gets worse or you experience any
      intolerable side effects, you will be taken off the study and your doctor will discuss other
      treatment options with you.

      This is an investigational study. Nilotinib is FDA approved. A total of 150 patients will
      take part in this study. All will be enrolled at MD Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 27, 2005</start_date>
  <completion_date type="Actual">July 11, 2018</completion_date>
  <primary_completion_date type="Actual">July 11, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants With Complete Molecular Response (Molecular CR)</measure>
    <time_frame>12 months</time_frame>
    <description>Polymerase chain reaction (PCR) Ratio BCR-Abl/Abl of 0% after 12 months of therapy with Nilotinib by international standard.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Complete Cytogenetic Response (CCyR)</measure>
    <time_frame>6 months</time_frame>
    <description>Complete hematologic remission classified according to suppression of Philadelphia chromosome (Ph) by cytogenetics or i Fluorescence in situ hybridization (FISH)
No cytogenetic response - Ph positive 100%
Minor cytogenetic response - Ph positive 35-90%
Partial cytogenetic response - Ph positive 1-34%
Complete cytogenetic response - Ph positive 0% Major cytogenetic response = complete + partial (Ph positive &lt;35%)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">148</enrollment>
  <condition>Leukemia, Myelogenous, Chronic</condition>
  <arm_group>
    <arm_group_label>Nilotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg orally twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilotinib</intervention_name>
    <description>400 mg orally twice daily</description>
    <arm_group_label>Nilotinib</arm_group_label>
    <other_name>Tasigna®</other_name>
    <other_name>AMN107</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of Ph-positive or Bcr-positive CML in early chronic phase CML (i.e., time
             from diagnosis 12 months). Except for hydroxyurea, patients must have received no or
             minimal prior therapy, defined as &lt;1 month (30 days) of prior interferon-alpha (with
             or without cytarabine) and/or an FDA-approved Tyrosine Kinase Inhibitor (TKI).
             Patients with de novo accelerated phase will be treated but analyzed separately.

          2. Age &gt;/= 16 years (Age &gt;18 years to participate in optional symptom burden assessment)

          3. Eastern Cooperative Oncology (ECOG) performance of 0-2.

          4. Adequate end organ function, defined as the following: total bilirubin &lt; 1.5 x upper
             limit of normal (ULN), alanine aminotransferase (ALT/SGPT) &lt; 2.5 x ULN, creatinine &lt;
             1.5 x ULN.

          5. Patients must sign an informed consent indicating they are aware of the
             investigational nature of this study, in keeping with the policies of the hospital.

          6. Reliable telephone access to receive calls from an interactive voice response system
             (IVR) (only applicable to patients who will participate in optional symptom burden
             assessment).

        Exclusion Criteria:

          1. New York Heart Association (NYHA) cardiac class 3-4 heart disease as well as impaired
             cardiac function defined as: left ventricular ejection fraction (LVEF) &lt; 45% as
             determined by Multigated Acquisition Scan (MUGA) scan or electrocardiogram; Complete
             left bundle branch block; Use of cardiac pacemaker; ST depression of &gt; 1 mm in 2 or
             more leads and/or T wave inversions in 2 or more continuous leads; Congenital long QT
             syndrome; History of, or presence of significant ventricular or atrial
             tachyarrhythmia's; Clinically significant resting bradycardia (&lt; 50 bpm); QTc &gt; 450
             msec on screening ECG (using the QTcF formula);

          2. (Continued from #1) Right bundle branch block plus left anterior hemiblock, bivascular
             block; Myocardial infarction within 12 months prior to starting AMN107; Unstable
             angina diagnosed or treated within the past 12 months; Other clinically significant
             heart disease (e.g. congestive heart failure, uncontrolled hypertension, history of
             labile hypertension, or history of poor compliance with an antihypertensive regimen).

          3. Patients with active, uncontrolled psychiatric disorders including: psychosis, major
             depression, and bipolar disorders.

          4. Female patients of childbearing potential must have negative pregnancy test within 7
             days before initiation of study drug dosing. Postmenopausal women must be amenorrheic
             for at least 12 months to be considered of non-childbearing potential. Surgical
             sterilization is considered non-childbearing potential. Female patients of
             reproductive potential must agree to employ an effective method of birth control
             (hormonal or barrier) throughout the study and for up to 3 months following
             discontinuation of study drug.

          5. Patients with severe and/or uncontrolled medial disease (i.e., uncontrolled diabetes,
             chronic renal disease, or active uncontrolled infection [persistent fever and
             worsening clinical condition]).

          6. Patient with known chronic liver disease (i.e., chronic active hepatitis, and
             cirrhosis).

          7. Patient with known diagnosis of human immunodeficiency virus (HIV) infection.

          8. Patients in late chronic phase (i.e., time from diagnosis to treatment &gt;12 months) or
             blastic phase are excluded. The definitions of CML phases are as follows: A. Early
             chronic phase: time from diagnosis to therapy &lt; 12 months Late chronic phase: time
             from diagnosis to therapy &gt; 12 months.B. Blastic phase: presence of 30% blasts or more
             in the peripheral blood or bone marrow. C. Accelerated phase CML: presence of any of
             the following features: * Peripheral or marrow blasts 15% or more.

          9. (Cont. #8)Peripheral or marrow basophils 20% or more. *Thrombocytopenia &lt; 100 x
             10(9)/L unrelated to therapy. * Documented extramedullary blastic disease outside
             liver or spleen due to past causes D. Clonal evolution defined as the presence of
             additional chromosomal abnormalities other than the Ph chromosome is part of
             accelerated phase CML. Ph chromosome variants or complex Ph chromosome translocations
             are not considered to indicate disease acceleration.

         10. ( Cont # 8) We have recently found clonal evolution to have a variable prognostic
             impact and may be suppressed with Interferon therapy (IFN-a therapy). Hence these
             patients, like others with de novo accelerated phase, will be eligible, and analyzed
             separately.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorge Cortes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 11, 2005</study_first_submitted>
  <study_first_submitted_qc>August 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2005</study_first_posted>
  <results_first_submitted>August 19, 2019</results_first_submitted>
  <results_first_submitted_qc>August 19, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 11, 2019</results_first_posted>
  <last_update_submitted>September 16, 2019</last_update_submitted>
  <last_update_submitted_qc>September 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic phase CML</keyword>
  <keyword>Newly diagnosed chronic phase CML</keyword>
  <keyword>AMN107</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 13, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/40/NCT00129740/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Nilotinib</title>
          <description>400 mg orally twice daily
Nilotinib: 400 mg orally twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="148"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="148"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nilotinib</title>
          <description>400 mg orally twice daily
Nilotinib: 400 mg orally twice daily</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="148"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51" lower_limit="17" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="134"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participants With Complete Molecular Response (Molecular CR)</title>
        <description>Polymerase chain reaction (PCR) Ratio BCR-Abl/Abl of 0% after 12 months of therapy with Nilotinib by international standard.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nilotinib</title>
            <description>400 mg orally twice daily
Nilotinib: 400 mg orally twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Complete Molecular Response (Molecular CR)</title>
          <description>Polymerase chain reaction (PCR) Ratio BCR-Abl/Abl of 0% after 12 months of therapy with Nilotinib by international standard.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Complete Cytogenetic Response (CCyR)</title>
        <description>Complete hematologic remission classified according to suppression of Philadelphia chromosome (Ph) by cytogenetics or i Fluorescence in situ hybridization (FISH)
No cytogenetic response - Ph positive 100%
Minor cytogenetic response - Ph positive 35-90%
Partial cytogenetic response - Ph positive 1-34%
Complete cytogenetic response - Ph positive 0% Major cytogenetic response = complete + partial (Ph positive &lt;35%)</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nilotinib</title>
            <description>400 mg orally twice daily
Nilotinib: 400 mg orally twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Complete Cytogenetic Response (CCyR)</title>
          <description>Complete hematologic remission classified according to suppression of Philadelphia chromosome (Ph) by cytogenetics or i Fluorescence in situ hybridization (FISH)
No cytogenetic response - Ph positive 100%
Minor cytogenetic response - Ph positive 35-90%
Partial cytogenetic response - Ph positive 1-34%
Complete cytogenetic response - Ph positive 0% Major cytogenetic response = complete + partial (Ph positive &lt;35%)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 11.5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Nilotinib</title>
          <description>400 mg orally twice daily
Nilotinib: 400 mg orally twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>CNS Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Chest Pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Cardiac ischemia/infarction</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Valvular heart disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>GI Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Hemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Abdoninal Pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Acute Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Small Bowel Obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Flu like Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecyctitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Elevated Creatinine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Elevated Transaminases</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Left Buccal Squamous Cell Carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Neoplasm squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Secondary Malignancy - Prostate Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CNS Ischemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Persomality/behavioral -alcohol treatment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Psychosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urethra Stricture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Revision right hip arthroplasty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Knee Replacement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Angioplasty with Stent Placement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Hip Replacement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Vascular Stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="148" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular Ischemia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="65" subjects_affected="65" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Elevated bilirubin</sub_title>
                <counts group_id="E1" events="84" subjects_affected="84" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Elevated Aminotransferases</sub_title>
                <counts group_id="E1" events="71" subjects_affected="71" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="76" subjects_affected="76" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="30" subjects_affected="26" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Cortes,Jorge E, MD./Professor</name_or_title>
      <organization>The University of Texas MD Anderson Cancer Center</organization>
      <phone>713-794-5783</phone>
      <email>jcortes@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

